IPC has filed a patent application on behalf of client, Sensiva Health, covering a proprietary algorithm of testing COVID-19 patients using a combination of available diagnostics, public health data and eventual vaccination data to risk stratify individuals so they may return to the workforce and begin to interact normally with others while still minimizing the future impact of possible reinfection.
According to Jim Silliman, MD, President of Sensiva Health, "We developed our risk stratification method with the goal of enabling employers, local, and federal agencies to implement a testing plan to have citizens more safely return to work and community during the COVID-19 pandemic."
IPC has sought expedited examination of the patent application for its client, and through Sensiva's affiliate Cormeum Lab Services, LL,C, has filed for Emergency Use Authorization through the U.S. Food and Drug Administration. At this time, Sensiva's COVID-19 PCR+Antigen/Antibody Test is only available through medical professionals. Read more here.
IPC attorneys routinely assist clients with obtaining patents for their proprietary methods and inventions. If you are interested in learning more about patent protection, call our professionals at (504) 322-7126.